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ABSTRACT _
Lipid-lowering therapy can account for 7% of per patient
per month drug costs. Because this can be a significant
proportion of a payer's drug expenditure, this class of
drugs attracts payers' attention and thus becomes a focus
of efforts designed to control drug expenditures. Phar-
macy benefit managers (PBMs) use several techniques
and capabilities to affect the use of these drugs to improve
overall medical care and to capture financial opportuni-
ties. There is a gap between the marketplace needs for
As the name implies, pharmacy benefit managers(PBMs) are organizations that provide services
to manage a pharmacy benefit for a plan sponsor. A
pharmacy benefit is "managed" when actions are
taken both to ensure access to quality pharmaceuti-
cals and to create and capture financial opportuni-
ties (i.e., enabling the plan sponsor to attain a high
degree of value). The techniques and capabilities
used by PBMs are much like those used by hospi-
tals, clinics, integrated healthcare systems, managed
care organizations, and physician organizations.
PBMs serve a diverse market, which includes self-
funded employers, government agencies, managed
care organizations, insurance carriers, and union,
health, and welfare trusts. PBMs, however, are not
homogeneous entities, as there can be significant
variability in the programs, services, and capabilities
they provide. Because of this variability, the discus-
sion that follows pertains to the model and perspec-
tive of Merck-Medco, which may not be representa-
tive of every organization that provides pharmacy
benefit management services. Merck-Medco cur-
rently provides its services to more than 2000 differ-
ent plans covering over 50 million eligible members.
Lipid-lowering therapy attracts the attention of
payers of prescription drugs for two reasons. First,
Merck-Medco estimates that this class of drugs can
represent 7% of the total per member per month
(PMPM) drug expenditure (data on file, Merck-
Medco, Montvale, NJ). PMPM drug expenditures
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lipid therapy value information and current pharmaco-
economic evaluations of lipid therapy. The measurement
units that current pharmacoeconomic analyses tend to
use are not necessarily intuitive and do not easily conform
to the existing conceptual framework of policy makers.
The successful evaluation of PBM activities will be con-
tingent on a recognizable and widely accepted quantita-
tive measurement framework.
are used by managed care organizations to evaluate
the performance of PBMs. Hence, payers can bene-
fit significantly from any efforts to capture financial
opportunities and to reduce any unnecessary utili-
zation. The other reason relates to the effect of the
lipid-lowering agents on cardiovascular disease.
When used appropriately, these drugs can reduce
cardiovascular morbidity and mortality, which can
favorably affect both humanistic and financial ob-
jectives. Therefore, payers are interested in encour-
aging the use of these agents when appropriate. The
following discussion highlights the approaches used
to achieve a balance between appropriate utiliza-
tion and capturing financial opportunities.
Formulary Management
A formulary is a dynamic, select list of drugs plus
accompanying information necessary to address the
health interests of the patient and the financial ob-
jectives of the payer. Formulary management is use-
ful for lipid therapies, because there are several drugs
within each class of medication, such as 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitors ("statins"), bile-acid sequestrants,
and fibric acid derivatives. Within a certain class, a
list of drugs can be compiled to address the needs
of patients and also to create a competitive lever-
age for better pricing from manufacturers. Payers
can choose to implement formularies as open, in-
centive, or closed. When implemented as an open
formulary, coverage is not determined by formu-
lary status: the formulary in these cases becomes a
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medium to inform prescribers and patients about
which therapeutic options exist and which repre-
sent economic value. When implemented as an in-
centive formulary, the level of coverage is deter-
mined by formulary status (i.e., copayments are
typically higher for nonformulary drugs); and, when
implemented as a closed formulary, coverage is pro-
vided only for formulary drugs. Incentive and closed
formularies tend to be more efficient than open for-
mularies in affecting utilization, but they require an
environment conducive to effective communication.
To design formularies, a pharmacy and thera-
peutics committee is integral to determining the
content that will meet the clinical needs of the pa-
tients. The Pharmacy and Therapeutics Commit-
tee organized by Merck-Medco is an independent
group of specialists who are not employees of the
company. The committee determines which drugs
are necessary .for physicians to successfully and ef-
ficiently manage lipid disorders.
Drug Utilization Review
Drug utilization review (DUR) can be defined as an
authorized review of drug utilization according to
predetermined standards. DUR can be used by a
PBM to address both therapeutic and benefit man-
agement issues. Through different available means,
information on therapeutic duplicates, drug inter-
actions, dosing, compliance, and under-utilization
can be obtained and any problems detected may be
addressed. These issues certainly apply to lipid-low-
ering therapies.
With the DUR mechanism, both concurrent and
retrospective approaches can be used to address
utilization. Concurrent DUR allows prescription
changes to be made before the patient receives the
medication, that is, at the time when a prescription
is written or submitted to a pharmacy. In retrospec-
tive DUR, pharmacy claims can be searched on a
regular basis for certain utilization patterns. Prob-
lems thus detected can subsequently be addressed.
Prior Authorization
Every prescription must pass certain levels of au-
thorization for payment by a benefit plan sponsor.
Typically, enough information is available about
patient eligibility and drug coverage in an ordinary
claims transaction such that authorization can be
determined on-line immediately. However, in some
circumstances, drugs may be prescribed for indica-
tions other than those specified within the scope of
the benefit plan, thus leading to unnecessary costs.
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Prior authorization involves interrupting the ordi-
nary claims processing transaction for the purpose
of obtaining additional information to determine
eligibility for coverage. There are not many appli-
cations for this approach in the management of
lipid-lowering drugs. A plan sponsor could use
this approach to implement a plan design that
covers certain lipid-lowering drugs only when oth-
ers have not been effective or are otherwise not
appropriate.
The following concerns should be balanced with
the potential gains provided by prior authorization:
• The nature and basis of the inquiry necessary to
determine eligibility is not always welcomed by
prescribers, patients, and pharmacists.
• The staff, equipment, and technology required to
handle queries and verifications are expensive.
A careful analysis is necessary to evaluate the
appropriateness of this method. Prior authoriza-
tion might not be an ideal tool in the management
of lipid-lowering therapies.
Demand Management
Demand management is a mechanism whereby
members have access to information, usually through
phone lines staffed by trained personnel such as
nurses. The objective is to provide to members infor-
mation that enables them to determine which treat-
ment options are most appropriate. Merck-Medco
has linked pharmacy claims and different clinical
rule sets in a program called Well Informed. Thus,
for members with both the pharmacy benefit and the
Well Informed benefit, the staff is alerted when a
drug could be associated with a symptom or condi-
tion presented by the member. This information
could be used to facilitate and aid physician diag-
noses. The method can also be used to address bene-
fit management issues, such as directing patients to-
ward generic or preferred drugs, and it could be used
to advance self-management practices such as com-
pliance with lipid-lowering therapies.
Disease Management
From a PBM perspective, disease management is a
means to combine in a rational way the capabilities
of the organization to affect the objectives of a dis-
ease treatment program. In the lipid therapy area,
disease management would encompass several of
the components discussed here in a way that would
benefit patients and plan sponsors. A possible con-
figuration could include the following:
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• Patient information in the form of regular news-
letters on cardiovascular disease;
• Cardiovascular drug compliance messages and
reminders to patients;
• Patient-specific drug utilization review messages
to prescribers discussing both therapeutic issues
and opportunities to lower the cost of therapy;
• Access to individual counseling for patients on
such subjects as diet and drug therapies;
• Assessments of individual patient barriers to com-
pliance with customized solutions to patients;
• Formulary management of the lipid-lowering
category to provide the necessary drugs for suc-
cessful treatment and to create and capture fi-
nancial opportunities.
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Profiling and Feedback
Profiling and feedback to prescribers may provide
a broader perspective of existing problems and
prescribing patterns. Information from claims can
be used to profile individual physicians, providing
feedback to them as to how they compare to peers.
This is a way of addressing therapeutic, benefit-man-
agement, and disease-management issues. For ex-
ample, physicians can be provided with informa-
tion on the rate of prescribing certain classes of
lipid-lowering drugs. Comparison with prescrip-
tion patterns of other physician specialists in the
region is possible.
Table I Survey of 6335 patients with less than 80%
compliance to lipid-lowering therapy
Case Management
Case management involves initiatives that are local
and unique for each patient. It can encompass dis-
cussions with patients to find means of improving
lipid control, as well as discussions with providers
to find other opportunities and issues that can be
addressed immediately. For example, one such issue
is compliance. The information in Table 1 was gath-
ered from Merck-Medco surveys and lists patient
opinions about lipid-lowering therapy and some
reasons for noncompliance in a group of patients in
which compliance was less than 80%. Despite the
majority of patients feeling that lipid-lowering ther-
apy is important, they cited multiple reasons for fail-
ing to comply with lipid-lowering treatment regi-
mens. Case management may be a very effective
methodology for the healthcare team to review is-
sues such as compliance with patients using lipid-
lowering therapy.
Comments
Reasons for noncompliance
Forgetfulness
Difficultdrug regimen
Others feel the drug is unnecessary
Problems with scheduling
Decided not to continue
Views on lipid-lowering
High cholesterol leads to heart attacks
Lowering cholesterol is important
Will need to take medication permanently
Comments about their treatment
Cholesterol was effectively being reduced
Patients had at least one barrier to compliance
Want more information
Source: data on file, Merck-Medco, Montvale, NJ.
Percent
Agreeing
24
22
15
12
5
97
97
85
84
84
71
Point of Care
Point of care is in actuality an information delivery
channel. This refers to having, in the physician's of-
fice, the technology to communicate directly with
the PBM service. Presently, less efficient modes of
communication are used, such as mail, phone, and
fax. The most efficient way would be to have direct
conversation while the prescription is being writ-
ten. This approach involves the technology to select
the proposed prescription and communicate in real
time about benefit management or therapeutic is-
sues, such as availability of generic and formulary
drugs, prior authorization requirements, dosing, or
drug interactions. The method would be a more in-
telligent, sophisticated, and efficient approach to
provide lipid-lowering therapy protocols and criti-
cal pathways.
Conclusions
The economics involved with each of the PBM ac-
tivities named above are as yet not well quantified.
In general, there is a belief that increasing utiliza-
tion of lipid-lowering drugs will decrease the eco-
nomic costs due to hospitalization and cardiovascu-
lar events, but the real impact of utilization of these
drugs has not been finally determined. The right
balance will involve methods to lower ingredient
costs of lipid-lowering drugs and methods to bring
about appropriate utilization, which may mean re-
ducing utilization in some patients and increasing
utilization in others. If only one third of drug-eligi-
ble patients are currently treated with lipid-lower-
ing therapy, as has been suggested, and all eligible
patients were to be successfully treated, the cost of
treatment would triple. To proceed with methods
to increase utilization, therefore, the decision-mak-
ers and those responsible for funding will require a
236
recognizable and acceptable unit of value. The units
that current pharmacoeconomic analyses tend to
use are not necessarily intuitive and do not easily
conform to the existing conceptual framework of
policy makers. The evaluation of PBM activities
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will be conditional on a recognizable and accepted
quantitative measure.
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